Related Experiment Video

Updated: Jul 20, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Cardiac risk factors and potential treatments in Alzheimer's disease

Christine Bergmann1, Mary Sano

  • 1Alzheimer Disease Research Center of Mount Sinai School of Medicine, NYC, James J Peters VAMC, Bronx, NY 10468, USA.

Neurological Research
|September 2, 2006
PubMed

Insights

Preventing dementia, including Alzheimer's disease, may be possible by managing cardiovascular risks like hypertension, high cholesterol, and diabetes. Early interventions targeting these factors show promise for reducing cognitive decline in older adults.

Area of Science:

  • Neurology
  • Public Health
  • Geriatrics

Background:

  • Dementia is a prevalent neurological disorder in the elderly.
  • Increasing global longevity presents a significant public health challenge for dementia prevention.
  • Identifying modifiable risk factors is crucial for developing interventions.

Purpose of the Study:

  • To review the relationship between cardiovascular risk factors and cognitive decline.
  • To examine hypertension, hyperlipidemia, and diabetes mellitus as targets for preventing dementia, including Alzheimer's disease.
  • To assess the impact of related medications on cognitive health.

Main Methods:

  • Review of observational studies and clinical trials.
  • Focus on antihypertensive, lipid-lowering, and antidiabetic medications.
  • Analysis of associations with cognitive impairment, dementia, and Alzheimer's disease risk.

Main Results:

  • Cardiovascular risk factors are linked to cognitive decline and dementia.
  • Medications targeting these factors are reviewed for their effect on cognition.
  • Evidence suggests a potential benefit of managing these risks.

Conclusions:

  • Early intervention to reduce cardiovascular risk factors may impact dementia incidence.
  • Managing hypertension, hyperlipidemia, and diabetes is a potential strategy for dementia prevention.
  • This approach may help reduce the future prevalence of cognitive deficits, including Alzheimer's disease.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...